Product description:

Subsequent studies have confirmed the effectiveness of cabergoline for the treatment of prolactinomas, with few side effects in most patients. It is now considered first-line therapy, except in patients with contraindications, such as in women who are pregnant or desire to become pregnant, and patients with psychiatric disease. There have also been studies to suggest that in a minority of patients, impulsivity and risk-taking behaviors may increase. Finally, there are data to suggest that at high doses, not usually prescribed to patients with pituitary tumors, cardiac valve dysfunction can occur.
In summary, cabergoline appears to be a more effective and better tolerated dopamine agonist in the therapy of prolactinomas. Patient compliance is high, related to the few mild side effects and once-weekly dosing.